AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12949996 — intervention group
Group type: COMPARATOR
Intervention: Gepirone extended-release (gepirone-ER, types 1, 2, and 3)
Number of subjects: 0
Study 12949996 — intervention group
Group type: COMPARATOR
Intervention: Gepirone extended-release (gepirone-ER)
Number of subjects: 0
Study 10791521 — intervention group
Group type: COMPARATOR
Intervention: Poractant alfa
Number of subjects: 212
Study 10791521 — intervention group
Group type: EXPERIMENTAL
Intervention: Pumactant
Number of subjects: 212
Study 9493922 — intervention group
Group type: EXPERIMENTAL
Intervention: Home polysomnographic studies
Number of subjects: 64
Study 9493922 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory polysomnographic studies
Number of subjects: 64
Study 8150761 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime 2.0 g bd i.v.
Number of subjects: 348
Study 8150761 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime 2.0 g tid i.v.
Number of subjects: 348
Study 3079597 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 ng/kg GnRH
Number of subjects: 18
Study 3079597 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ng/kg GnRH
Number of subjects: 18
Study 29182426 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT) performed two times per week (G2X)
Number of subjects: 39
Study 29182426 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (RT) performed three times per week (G3X)
Number of subjects: 39
Study 29182426 — intervention group
Group type: COMPARATOR
Intervention: Both G2X and G3X
Number of subjects: 39
Study 27248138 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting session (FS)
Number of subjects: 21
Study 27248138 — intervention group
Group type: COMPARATOR
Intervention: Control session (CS)
Number of subjects: 21
Study 26161469 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Number of subjects: 75
Study 26161469 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study 23718760 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 180
Study 23718760 — intervention group
Group type: COMPARATOR
Intervention: General Psychiatric Management (GPM)
Number of subjects: 180
Study 20409606 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 0.5mg daily
Number of subjects: 167
Study 18431235 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid therapy (15 mg/day of methyltertrahydrofolate for 1 year)
Number of subjects: 51
Study 18431235 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 51
Study 18431235 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid therapy
Number of subjects: 51
Study 18431235 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid therapy in high-risk subgroup (older recipients and those with coronary artery disease)
Number of subjects: 51
Study 18431235 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid therapy in lower-risk subgroup
Number of subjects: 51
Study 16644433 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler tissue imaging
Number of subjects: 40
Study 12718214 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (20 mg/day for 20 days)
Number of subjects: 40
Study 12718214 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled benacort (400 micrograms twice a day for 20 days)
Number of subjects: 40
Study 12718214 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 healthy subjects)
Number of subjects: 40
Study 10692234 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART plus IL-2
Number of subjects: 22
Study 10692234 — intervention group
Group type: COMPARATOR
Intervention: HAART
Number of subjects: 22
Study 9379380 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobunolol 0.5%
Number of subjects: 144
Study 9379380 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol 0.5%
Number of subjects: 144
Study 9379380 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 144
Study 8471327 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant combination chemotherapy (AMF); 5‐fluorouracil 500 mg/m2, doxorubicin 40 mg/m2, mitomycin C 6 mg/m2 (n = 30) once every 3 weeks for six cycles
Number of subjects: 61
Study 8471327 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvant chemotherapy) (n = 31)
Number of subjects: 61
Study 8471327 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant combination chemotherapy (AMF)
Number of subjects: 61
Study 8471327 — intervention group
Group type: COMPARATOR
Intervention: Control group (no adjuvant chemotherapy)
Number of subjects: 61
Study 3898908 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural fentanyl (80 micrograms in the epidural test dose of bupivacaine)
Number of subjects: 20
Study 3898908 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fentanyl (infusion designed to produce comparable plasma concentrations)
Number of subjects: 20
Study 30413866 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up postoperative call (FPC) policy, implemented within 48 to 72 hours of discharge
Number of subjects: 459
Study 30413866 — intervention group
Group type: COMPARATOR
Intervention: Control group (no follow-up call)
Number of subjects: 459
Study 30413866 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up postoperative call (FPC) policy
Number of subjects: 459
Study 28594249 — intervention group
Group type: EXPERIMENTAL
Intervention: School nurse-administered inhaled corticosteroids (ICS)
Number of subjects: 46
Study 28594249 — intervention group
Group type: COMPARATOR
Intervention: Control (home-administered ICS)
Number of subjects: 46
Study 26149243 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention program
Number of subjects: 0
Study 25891550 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular interferon beta-1a (IM IFNβ‐1a) 30 μg
Number of subjects: 37
Study 25891550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 22857881 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional support with whey peptide and low-intensity exercise therapy
Number of subjects: 36
Study 22857881 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nutritional support)
Number of subjects: 36
Study 20300048 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 233
Study 20300048 — intervention group
Group type: EXPERIMENTAL
Intervention: Other antihypertensive drug monotherapies
Number of subjects: 233
Study 20300048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study 18400141 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 microg kg(‐1) in 10 mL normal saline)
Number of subjects: 52
Study 18400141 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (1 microg kg(‐1) in 10 mL normal saline)
Number of subjects: 52
Study 16088821 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 20
Study 16088821 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk concentrations of nevirapine
Number of subjects: 20
Study 16088821 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk concentrations of lamivudine
Number of subjects: 20
Study 16088821 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk concentrations of zidovudine
Number of subjects: 20
Study 16088821 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine in infants
Number of subjects: 20
Study 16088821 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamivudine in infants
Number of subjects: 20
Study 16088821 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine in infants
Number of subjects: 20
Study 11985532 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA) or Mycophenolate mofetil (MMF) after conversion from Cyclosporin A (CsA)
Number of subjects: 0
Study 11985532 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose immunosuppression (after tapering)
Number of subjects: 0
Study 10884453 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase (1.5 million units)
Number of subjects: 1292
Study 10884453 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 1292
Study 9307633 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% carbomer gel
Number of subjects: 123
Study 9307633 — intervention group
Group type: COMPARATOR
Intervention: placebo (mannitol solution with benzalkonium chloride 0.008%)
Number of subjects: 123
Study 9307633 — intervention group
Group type: COMPARATOR
Intervention: carbomer gel and placebo
Number of subjects: 123
Study 8320576 — intervention group
Group type: EXPERIMENTAL
Intervention: Long program (2 1/2‐day course)
Number of subjects: 53
Study 8320576 — intervention group
Group type: COMPARATOR
Intervention: Short program (4 1/2‐hour workshop)
Number of subjects: 53
Study 3330183 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 treatment
Number of subjects: 38
Study 3330183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 31562660 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring letters (CL) intervention - 13 caring e‐mails over two years
Number of subjects: 1318
Study 31562660 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1318
Study 31562660 — intervention group
Group type: EXPERIMENTAL
Intervention: Caring letters (CL) intervention
Number of subjects: 1318
Study 30430649 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001 (6 × 10^9 cfu)
Number of subjects: 0
Study 30430649 — intervention group
Group type: COMPARATOR
Intervention: Bifidobacterium lactis HN019 (9 × 10^9 cfu)
Number of subjects: 0
Study 27309886 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (240 mg in 125 mL saline solution)
Number of subjects: 0
Study 27309886 — intervention group
Group type: COMPARATOR
Intervention: Control group (125 mL saline solution)
Number of subjects: 0
Study 27309886 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (lidocaine and control)
Number of subjects: 0
Study 24360787 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin and cyclophosphamide then paclitaxel
Number of subjects: 831
Study 24360787 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel with or without gemcitabine followed by epirubicin and cyclophosphamide
Number of subjects: 831
Study 24360787 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin and cyclophosphamide first
Number of subjects: 831
Study 24360787 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and gemcitabine then epirubicin and cyclophosphamide
Number of subjects: 831
Study 24360787 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 831
Study 22759250 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-1 (Belotero Basic/Balance)
Number of subjects: 20
Study 22759250 — intervention group
Group type: COMPARATOR
Intervention: HA-2 (Restylane)
Number of subjects: 20
Study 22759250 — intervention group
Group type: COMPARATOR
Intervention: HA-3 (Juvéderm Ultra 3/Juvéderm Ultra Plus XC)
Number of subjects: 20
Study 20067650 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolisation
Number of subjects: 23
Study 20067650 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic resection without embolisation
Number of subjects: 23
Study 18068284 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0
Study 18068284 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial treatments
Number of subjects: 0
Study 18068284 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatments (Methylphenidate + Psychosocial treatments)
Number of subjects: 0
Study 18068284 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (Methylphenidate, Psychosocial treatments, Combined treatments)
Number of subjects: 0
Study 15528979 — intervention group
Group type: EXPERIMENTAL
Intervention: Single doses of GW572016
Number of subjects: 35
Study 15528979 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses of GW572016 (25 mg, 100 mg, 175 mg)
Number of subjects: 35
Study 15528979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 12629229 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha‐[11C] methyl‐L‐tryptophan (alpha‐MTrp) PET
Number of subjects: 14
Study 12629229 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐[18F]‐fluoro‐deoxy‐glucose (FDG) PET
Number of subjects: 14
Study 12629229 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG PET
Number of subjects: 14
Study 12629229 — intervention group
Group type: COMPARATOR
Intervention: alpha‐MTrp PET
Number of subjects: 14
Study 10562777 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane anaesthesia at 1.2 MAC
Number of subjects: 14
Study 10562777 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anaesthesia at 1.2 MAC
Number of subjects: 14
Study 10562777 — intervention group
Group type: COMPARATOR
Intervention: Awake state
Number of subjects: 14
Study 10562777 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane anaesthesia
Number of subjects: 14
Study 10562777 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anaesthesia
Number of subjects: 14
Study 10562777 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions (awake and anaesthetized)
Number of subjects: 14
Study 8561642 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-coated oxygenator
Number of subjects: 60
Study 8561642 — intervention group
Group type: COMPARATOR
Intervention: Bubble oxygenator
Number of subjects: 60
Study 8561642 — intervention group
Group type: COMPARATOR
Intervention: Hollow-fiber oxygenator
Number of subjects: 60
Study 1888786 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% oxygen via a venturi mask during transport
Number of subjects: 0
Study 1888786 — intervention group
Group type: COMPARATOR
Intervention: Room air (control group)
Number of subjects: 0
Study 31580552 — intervention group
Group type: EXPERIMENTAL
Intervention: Water pipe smoking (WP)
Number of subjects: 500
Study 31580552 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 500
Study 27886013 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized music intervention
Number of subjects: 22
Study 27886013 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory stimulation environment (MSSE)
Number of subjects: 22
Study 27886013 — intervention group
Group type: COMPARATOR
Intervention: Comparison between individualized music and MSSE
Number of subjects: 22
Study 27886013 — intervention group
Group type: COMPARATOR
Intervention: Correlation with agitation, anxiety, cognitive function, and dementia severity
Number of subjects: 22
Study 25871602 — intervention group
Group type: EXPERIMENTAL
Intervention: Teleconference-delivered fatigue management program
Number of subjects: 81
Study 24060179 — intervention group
Group type: EXPERIMENTAL
Intervention: p16 positivity
Number of subjects: 336
Study 24060179 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR expression (low)
Number of subjects: 336
Study 24060179 — intervention group
Group type: EXPERIMENTAL
Intervention: EGFR expression
Number of subjects: 336
Study 24060179 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of EGFR/p16
Number of subjects: 336
Study 21263371 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin (two doses during removal of the catheter)
Number of subjects: 88
Study 21263371 — intervention group
Group type: COMPARATOR
Intervention: No antimicrobial agent (control group)
Number of subjects: 88
Study 19208352 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate (LC) diet (<50 g/day)
Number of subjects: 22
Study 19208352 — intervention group
Group type: COMPARATOR
Intervention: Low-fat, high-carbohydrate (HC) diet (>180 g/day)
Number of subjects: 22
Study 18667140 — intervention group
Group type: EXPERIMENTAL
Intervention: Various nonpharmacologic interventions and therapies tried by patients, including assessment of success rates and patient function.
Number of subjects: 0
Study 18667140 — intervention group
Group type: EXPERIMENTAL
Intervention: Establishment of a secure physician-patient relationship and open communication.
Number of subjects: 0
Study 15363824 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (20 nonpharmacologic, 36 beta‐blockers, 33 angiotensin receptor blocker)
Number of subjects: 89
Study 15363824 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment after 12 months
Number of subjects: 89
Study 11181662 — intervention group
Group type: EXPERIMENTAL
Intervention: IV carboplatin (area under curve 9) every 28 days for two courses, then IV paclitaxel 135 mg/m(2) over 24 hours followed by intraperitoneal (IP) cisplatin 100 mg/m(2) every 3 weeks for six courses
Number of subjects: 462
Study 11181662 — intervention group
Group type: COMPARATOR
Intervention: IV cisplatin 75 mg/m(2) every 3 weeks for six courses plus IV paclitaxel 135 mg/m(2) over 24 hours
Number of subjects: 462
Study 9692280 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Controlled Trials (RCTs)
Number of subjects: 1063
Study 9692280 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative studies or surveys
Number of subjects: 1063
Study 9692280 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal design studies
Number of subjects: 1063
Study 9692280 — intervention group
Group type: EXPERIMENTAL
Intervention: Organization and administration issues studies
Number of subjects: 1063
Study 8080345 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan-deficient amino acid mixture
Number of subjects: 39
Study 8080345 — intervention group
Group type: COMPARATOR
Intervention: Balanced amino acid mixture (placebo)
Number of subjects: 39
Study 2510287 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 150 micrograms
Number of subjects: 0
Study 2510287 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 300 micrograms
Number of subjects: 0
Study 2510287 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11960 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg lorazepam
Number of subjects: 21
Study 11960 — intervention group
Group type: COMPARATOR
Intervention: 20 mg papaveretum/400 mug hyoscine
Number of subjects: 21
Study 31722646 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with serious mental disorders
Number of subjects: 50551
Study 31722646 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched participants)
Number of subjects: 50551
Study 30999270 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluteus medius (GMED) activity in CAI group
Number of subjects: 20
Study 30999270 — intervention group
Group type: COMPARATOR
Intervention: Healthy counterparts (control group)
Number of subjects: 20
Study 28185260 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg sugammadex (Group S)
Number of subjects: 60
Study 28185260 — intervention group
Group type: COMPARATOR
Intervention: 0.35 mg/kg neostigmine and 0.02 mg/kg atropine (Group N)
Number of subjects: 60
Study 26378650 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally tailored, computer-delivered media-based intervention
Number of subjects: 216
Study 26378650 — intervention group
Group type: COMPARATOR
Intervention: Placebo comparison condition
Number of subjects: 216
Study 23380907 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture as adjunct to reversible occlusal splint therapy
Number of subjects: 40
Study 23380907 — intervention group
Group type: COMPARATOR
Intervention: Placebo laser associated with occlusal splint therapy
Number of subjects: 40
Study 21872490 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 88
Study 21872490 — intervention group
Group type: COMPARATOR
Intervention: Total Intravenous Anesthesia (TIVA)
Number of subjects: 88
Study 18362871 — intervention group
Group type: EXPERIMENTAL
Intervention: CBZ-ERC
Number of subjects: 155
Study 16533101 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey on perceived severity of childhood obesity
Number of subjects: 1047
Study 16533101 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for interventions such as regulation of restaurant portions and fast food advertising
Number of subjects: 1047
Study 16533101 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regressions examining differences in obesity attitudes
Number of subjects: 1047
Study 14557420 — intervention group
Group type: EXPERIMENTAL
Intervention: T4 plus T3
Number of subjects: 40
Study 14557420 — intervention group
Group type: COMPARATOR
Intervention: T4 plus placebo
Number of subjects: 40
Study 11202586 — intervention group
Group type: EXPERIMENTAL
Intervention: NHS breast screening programme (NHSBSP)
Number of subjects: 0
Study 10176125 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion (PP)
Number of subjects: 70
Study 10176125 — intervention group
Group type: COMPARATOR
Intervention: Nonpulsatile perfusion (NP)
Number of subjects: 70
Study 1490543 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation letter containing an appointment
Number of subjects: 872
Study 1490543 — intervention group
Group type: EXPERIMENTAL
Intervention: Invitation letter with high satisfaction ratings
Number of subjects: 872
Study 1490543 — intervention group
Group type: EXPERIMENTAL
Intervention: Health check intervention
Number of subjects: 872
Study 1490543 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response to health checks
Number of subjects: 872
Study 4037555 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly pulse methotrexate
Number of subjects: 12
Study 4037555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 28887640 — intervention group
Group type: EXPERIMENTAL
Intervention: G10 group received two IV doses of 10 mg/kg of TXA
Number of subjects: 80
Study 28887640 — intervention group
Group type: COMPARATOR
Intervention: G20 group received two doses of 20 mg/kg of TXA
Number of subjects: 80
Study 27275858 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive and informative method (Group A)
Number of subjects: 312
Study 27275858 — intervention group
Group type: COMPARATOR
Intervention: Learning method based on problems (Group B)
Number of subjects: 312
Study 25263395 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (12% ethanol, 1758 mg/L total polyphenols) for 4 weeks
Number of subjects: 34
Study 23051744 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean red ginseng (KRG) 7.5 g divided into three daily doses
Number of subjects: 28